NATX Plasmids, for: DNA Vaccines, Gene Therapeutics, Viral Vectors andBiophamacueticals

Vaccines and Adjuvants
DNA Vaccines: Providing vaccines in a pandemic timeframe

NTC Contacts:
Phone: (402) 323-6289 (natx)
Fax: (402) 323-6292
Email: support@natx.com

site map | home | contact us
NTC PRODUCTS AND SERVICES

MAMMALIAN EXPRESSION VECTORS
X• Antibiotic-Free Vectors
X• Rig-I Activating Vectors
X• Linear Vectors
X• Recombineering Vectors
X• Gene Silencing (transient)
X• Gene Silencing (retroviral, stable)
X• Anti-Silencing Elements
X• Vector Pricing

CELL LINES
X• Autolytic E. coli Cell Lines
X• dcm- Strains

VACCINES & ADJUVANTS
X• DNA Vaccines
X• Rig-I Activating DNA Vaccines
X• Thermostable Protein Expression

PRECISION CLONING
X• Services and Pricing

RECOMBINANT PROTEINS
X• pVEX™-E. coli Expression Vectors
X• Fluorescent Proteins
X• Products, Vectors, Services, Prices
X• CofA (SAMPLE)

PLASMIDS
X• Small Scale Plasmid DNA
X• Small Scale C of A
X• Large Scale Plasmid DNA
X• Large Scale C of A
X• Plasmid DNA Order Form
X• E. coli Cell paste
X• NEW! Plasmid Detox Service
X• Additional Testing

PROCESS DEVELOPMENT

DNA FERMENTATION PROCESS
X• HyperGRO™ Publications
X• E. coli Cell Paste

HYPERTAQ™ DNA POLYMERASE

CONTRACT QC
X• E. coli Genomic DNA Testing
X• Residual RNA qPCR
X• Residual RNA gel
X• Supercoil Assay
X• Lymulus Endotoxin Testing

NTC's, rapidly deployable set of DNA vaccination tools can be readily adapted to any antigens in a two-week, "precision cloning" turnaround service.
NTC's leading vector system offers the following improvments in DNA backbone architecture:
1.
Reduced genome (only essential sequences: increases potency, decreases recombination potential)
2.
Trafficking (DNA to the nucleus, protein to selected presentation pathways)
3.
Optimized expression via transcriptional and translational enhancement and a synthetic intron
4.
Antibiotic free (meets regulatory demands)
5.
Selected co-stimulators (activates antigen presentation, prevents tolerization)
6.
Highest yield in the fermentor (increases purity, cost effectiveness)

DNA Vaccine References

XXNTC Vector Advantages

A typical advanced NTC vector, NTC8685-EGFP, with the following features: markerless (sucrose selection), enhanced transcription (SV40/CMV), enhanced translation (CMV/HTLV-1-R), enhanced translation (VA1), enhanced plasmid production (PAS-BH).
A typical advanced NTC vector, NTC8685-EGFP, with the following features: markerless (sucrose selection), enhanced transcription (SV40/CMV), enhanced translation (CMV/HTLV-1-R), enhanced translation (VA1), enhanced plasmid production (PAS-BH).
• DNA Vaccination

• Therapeutic Vector

• Native Expression

• Secreted (TPA tag)

• Minimal Backbone

• Reporter (EGFP)

• Regulatory Compliance

• Simultaneous Cloning


Plus, choose from the following special advantages included on the Vector Selection Flowchart below.

XXVector Selection Flowchart

Selection
Transgene
Targeting
HTLV-I R
transient
expression
enhancer
VA1 transient
expression
enhancer
SV40-PAS-BH
increased
plasmid yield
backbone
RIG-I
activating
backbone
Vector
XKan XSecreted;
XGPI anchored;
XProteosome;
XEndosome;
Xor Native
No
No
No
No
 XpDNAVACCUltra
X Sucrose
XSecreted; or XNative
Yes
No
No
No
 XNTC8382
XNTC8385
XSucrose XSecreted; or XNative
Yes
Yes
No
No
 XNTC8382-VA1
XNTC8385-VA1
XKan XSecreted; or XNative
Yes
No
*Yes
No
 XNTC7482
XNTC7485
XKan XSecreted; or XNative
Yes
Yes
*Yes
Yes
 XNTC7482-eRNA41H
XNTC7485-eRNA41H
XSucrose
XSecreted; or XNative
Yes
No
 *Yes No XNTC8482
XNTC8485
XSucrose XSecreted; or XNative Yes Yes *Yes Yes XNTC8481-eRNA41H
XNTC8482-eRNA41H
XSucrose XSecreted; or XNative
Yes
Yes
*Yes
No
 XNTC8681
XNTC8682
XNTC8684
XNTC8685
XSucrose XSecreted; or XNative Yes Yes *Yes Yes XNTC8681-eRNA41H
XNTC8682-eRNA41H
XNTC8684-eRNA41H
XNTC8685-eRNA41H

*Save 20% off large scale production cost with NTC’s high-yield, SV40-PAS-BH vectors!
(for a limited time)
XXCompare NTC's vectors


EGFP transgene expression (fluorescence) in human HEK293 cell line after transfection of dcm+ or dcm- NTC8685, gWIZ and pVAX1 CMV promoter plasmid vectors.
Figure 1: EGFP transgene expression (fluorescence) in human HEK293 cell line after transfection of dcm+ or
dcm- NTC8685, gWIZ and pVAX1 CMV promoter plasmid vectors.



Figure 2: NTC8385-VA1 expression compared to gWIZ-EGFP and pVAX1-EGFP in HEK293 cells.

Figure 2: NTC8385-VA1 expression compared to gWIZ-EGFP and pVAX1-EGFP in HEK293 cells.
XXDNA Vaccine References


Williams, J.A., Luke, J., Johnson, L., Hodgson, C.P. (2006) pDNAVACCultra family:  High throughput intracellular targeting DNA vaccine plasmids. Vaccine 24:4671-4679.

Luke, J. Carnes, A.E., Hodgson, C.P., Williams, J.A. (2009) Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 27(46):6454-9.

Williams, J.A., Carnes, A.E., Hodgson, C.P. (2009) Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production. Biotechnol. Adv. 27:353-370.

Luke, J.M., Simon, G.G., Soderholm, J., Errett, J.S., August, J.T., Gale, J., Hodgson, C.P., Williams, J.A. (2011) Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza DNA Vaccine.  J. Virol. 85:1370-83.